Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes

Wilt, 2012, Radical prostatectomy versus observation for localized prostate cancer, N Engl J Med, 367, 203, 10.1056/NEJMoa1113162 Hamdy, 2016, 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 Adamy, 2011, Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer, J Urol, 185, 477 Carter, 2007, Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience, J Urol, 178, 2359 Kovac, 2018, Effects of pathological upstaging or upgrading on metastasis and cancer-specific mortality in men with clinical low-risk prostate cancer, BJU Int, 122, 1003, 10.1111/bju.14418 Moschini, 2017, Low-risk prostate cancer: identification, management, and outcomes, Eur Urol, 72, 238, 10.1016/j.eururo.2017.03.009 Castro, 2013, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer, J Clin Oncol, 31, 1748, 10.1200/JCO.2012.43.1882 Hsing, 2014, High prevalence of screen detected prostate cancer in West Africans: implications for racial disparity of prostate cancer, J Urol, 192, 730 Immediate versus deferred treatment for advanced prostatic cancer, 1997, initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group, Br J Urol, 79, 235, 10.1046/j.1464-410X.1997.d01-6840.x Zumsteg, 2017, Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer, BJU Int, 120, E87, 10.1111/bju.13903 Cooperberg, 2011, The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy, Cancer, 117, 5039, 10.1002/cncr.26169 Chen, 2016, Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario guideline): American Society of Clinical Oncology clinical practice guideline endorsement summary, J Oncol Pract, 12, 267, 10.1200/JOP.2015.010017 Musunuru, 2016, Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience, J Urol, 196, 1651 Thostrup, 2018, Active surveillance for localized prostate cancer: update of a prospective single-center cohort, Scand J Urol, 52, 14, 10.1080/21681805.2017.1380697 Thomsen, 2019, Active surveillance for localized prostate cancer: nationwide observational study, J Urol, 201, 520 Thomsen, 2019, Active surveillance versus radical prostatectomy in favorable-risk localized prostate cancer, Clin Genitourin Cancer, 17, e814, 10.1016/j.clgc.2019.05.005 Masic, 2018, Effects of initial Gleason grade on outcomes during active surveillance for prostate cancer, Eur Urol Oncol, 1, 386, 10.1016/j.euo.2018.04.018 Loeb, 2015, Five-year nationwide follow-up study of active surveillance for prostate cancer, Eur Urol, 67, 233, 10.1016/j.eururo.2014.06.010 Wilt, 2017, Follow-up of prostatectomy versus observation for early prostate cancer, N Engl J Med, 377, 132, 10.1056/NEJMoa1615869 Savdie, 2017, Identifying intermediate-risk candidates for active surveillance of prostate cancer, Urol Oncol, 35, 605.e1, 10.1016/j.urolonc.2017.06.048 Nyame, 2017, Intermediate-term outcomes for men with very low/low and intermediate/high risk prostate cancer managed by active surveillance, J Urol, 198, 591 Godtman, 2016, Long-term results of active surveillance in the Göteborg randomized, population-based prostate cancer screening trial, Eur Urol, 70, 760, 10.1016/j.eururo.2016.03.048 Yamamoto, 2016, Metastatic prostate cancer in men initially treated with active surveillance, J Urol, 195, 1409 Stattin, 2010, Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study, J Natl Cancer Inst, 102, 950, 10.1093/jnci/djq154 Cooperberg, 2011, Outcomes of active surveillance for men with intermediate-risk prostate cancer, J Clin Oncol, 29, 228, 10.1200/JCO.2010.31.4252 Bul, 2012, Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer, BJU Int, 110, 1672, 10.1111/j.1464-410X.2012.11434.x Herden, 2017, Risk stratification: a tool to predict the course of active surveillance for localized prostate cancer?, BJU Int, 120, 212, 10.1111/bju.13715 Shelton, 2019, Three-year active surveillance outcomes in a contemporary community urology cohort in the United States, Urology, 130, 72, 10.1016/j.urology.2019.04.017 Butler, 2019, Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer, Cancer, 125, 3164, 10.1002/cncr.32202 D’Amico, 1998, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 280, 969, 10.1001/jama.280.11.969 Spencer, 1998, Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer, Br J Radiol, 71, 1130, 10.1259/bjr.71.851.10434906 Kim, 2015, Potential utility of novel biomarkers in active surveillance of low-risk prostate cancer, Biomed Res Int, 2015, 475920, 10.1155/2015/475920 Bill-Axelson, 2018, Radical prostatectomy or watchful waiting in prostate cancer—29-year follow-up, N Engl J Med, 379, 2319, 10.1056/NEJMoa1807801 Dall’Era, 2017, Active surveillance for intermediate-risk prostate cancer, Prostate Cancer Prostatic Dis, 20, 1, 10.1038/pcan.2016.51 Washington, 2020, MRI-based prostate-specific antigen density predicts Gleason score upgrade in an active surveillance cohort, AJR Am J Roentgenol, 214, 574, 10.2214/AJR.19.21559 Giganti, 2019, DWI and PRECISE criteria in men on active surveillance for prostate cancer: a multicentre preliminary experience of different ADC calculations, Magn Reson Imaging, 67, 50, 10.1016/j.mri.2019.12.007 Page, 2019, Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers, Eur Urol, 76, 831, 10.1016/j.eururo.2019.08.019